Bio-Rad Laboratories, Inc. Share Price

Equities

BIO

US0905722072

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 20:12:18 16/07/2024 BST 5-day change 1st Jan Change
313.5 USD +3.77% Intraday chart for Bio-Rad Laboratories, Inc. +14.00% -2.95%
Sales 2024 * 2.66B 205B Sales 2025 * 2.8B 216B Capitalization 8.52B 657B
Net income 2024 * 294M 22.67B Net income 2025 * 285M 21.98B EV / Sales 2024 * 2.95 x
Net cash position 2024 * 674M 51.99B Net cash position 2025 * 828M 63.83B EV / Sales 2025 * 2.75 x
P/E ratio 2024 *
29.3 x
P/E ratio 2025 *
30.2 x
Employees 8,030
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.04%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.77%
1 week+14.00%
Current month+14.74%
1 month+5.95%
3 months+7.04%
6 months-0.59%
Current year-2.95%
More quotes
1 week
272.59
Extreme 272.585
313.41
1 month
262.12
Extreme 262.12
313.41
Current year
262.12
Extreme 262.12
364.24
1 year
261.59
Extreme 261.59
431.79
3 years
261.59
Extreme 261.59
832.70
5 years
261.59
Extreme 261.59
832.70
10 years
102.71
Extreme 102.71
832.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 74 31/12/88
Director of Finance/CFO 77 31/01/83
Chief Operating Officer 64 21/04/19
Members of the board TitleAgeSince
Director/Board Member 63 24/04/17
Founder 97 31/12/51
Director/Board Member 77 24/04/17
More insiders
Date Price Change Volume
16/07/24 313.8 +3.87% 88 926
15/07/24 302.1 -0.67% 231,378
12/07/24 304.2 +2.92% 301,850
11/07/24 295.5 +5.41% 246,549
10/07/24 280.4 +1.99% 225,782

Delayed Quote Nyse, July 16, 2024 at 07:56 pm

More quotes
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows: - manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems; - manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets; - other (0.1%): in particular, manufacturing of analytical instruments. At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore. Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
302.1 USD
Average target price
366.4 USD
Spread / Average Target
+21.28%
Consensus

Quarterly revenue - Rate of surprise